Organization (Industry)
LigaChem Biosciences, Inc. (South Korea)
ClinicalTrials.gov lists LigaChem Biosciences, Inc. (South Korea) as lead sponsor of 14 trials. It has 45 active development programs and 2 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.4 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers LigaChem Biosciences, Inc. (South Korea): 14 lead-sponsored trials and 1 legal-entity registration.
Disease areas (25)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Tuberculosis | 3 |
| Tuberculosis, Pulmonary | 3 |
| Breast Neoplasms | 2 |
| Endometrial Neoplasms | 2 |
| Lung Neoplasms | 2 |
Showing 5 of 25 disease areas.
Trials by start year as sponsor or collaborator (12)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 1 |
| 2024 | 1 |
| 2023 | 2 |
| 2022 | 1 |
| 2021 | 2 |
| 2020 | 1 |
| 2016 | 2 |
| 2015 | 2 |
| 2014 | 1 |
Showing 10 of 12 years.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (45)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Delpazolid | Inflammation | Phase 2 | 1 |
| Delpazolid | Mycobacterium Infections, Nontuberculous | Phase 2 | 1 |
| Bedaquiline, Delamanid, Moxifloxacin | Tuberculosis | Phase 2 | 1 |
| Bedaquiline, Delamanid, Moxifloxacin | Tuberculosis, Pulmonary | Phase 2 | 1 |
| Delpazolid | Tuberculosis | Phase 2 | 1 |
Showing 5 of 45 active programs.
Approved assets (2)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| VANCOMYCIN | 1 |
| LINEZOLID | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 80% hit target (n=5) | 0% on time (n=5) |
Journals published in (7)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Antimicrobial agents and chemotherapy | 2 |
| Clinical therapeutics | 2 |
| Journal of clinical pharmacology | 1 |
| The Journal of antimicrobial chemotherapy | 1 |
| The Lancet. Infectious diseases | 1 |
Showing 5 of 7 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 27 | 10 | 2025-08-26 |
Organization relationships (6)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| University of California System | Co sponsors trial with | 2 |
| Radboud University Medical Center | Co sponsors trial with | 2 |
| University of London | Co sponsors trial with | 1 |
| Ludwig-Maximilians-Universität München | Co sponsors trial with | 1 |
| Michael Hoelscher | Co sponsors trial with | 1 |
Showing 5 of 6 relationships.
Latest dated events (43)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-08 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-08-26 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-08-19 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-01-07 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-05-07 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 43 events.
Biomarker capability evidence (53)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial sponsor | Named in trial inclusion criteria |
| CLDN18 | Trial sponsor | Named in trial inclusion criteria |
| CSF2 | Trial sponsor | Named in trial inclusion criteria |
| CSF2 | Trial sponsor | Named in trial inclusion criteria |
| RHOF | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 53 evidence rows.
On Scientist.com
LigaChem Biosciences, Inc. (South Korea) is listed as a research supplier in the Scientist.com network.
Service areas
Legochem Biosciences, Inc. (LCB) is a pharmaceutical research service provider located in South Korea, offering comprehensive biological assays and medicinal chemistry supports to biotech, pharmaceutical companies and universities engaged in drug discovery and research. LCB focuses on fast turnaround time with efficient logistic and innovative synthesis route with high yield. Scientists at LCB are familiar and experienced with the challenges in drug discovery research and eager to be part of customer's discovery program in (i)strategic planning, (ii)hit evaluation and validation, (iii)lead...
Show the full description
Legochem Biosciences, Inc. (LCB) is a pharmaceutical research service provider located in South Korea, offering comprehensive biological assays and medicinal chemistry supports to biotech, pharmaceutical companies and universities engaged in drug discovery and research.
LCB focuses on fast turnaround time with efficient logistic and innovative synthesis route with high yield. Scientists at LCB are familiar and experienced with the challenges in drug discovery research and eager to be part of customer's discovery program in (i)strategic planning, (ii)hit evaluation and validation, (iii)lead optimization and (iv)preclinical development.
- Website
- www.legochembio.com
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.
Work with LegoChem Biosciences on Scientist.com
For prices, more details, or to contact LegoChem Biosciences, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.